Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Nov;24(5):812–814. doi: 10.1128/aac.24.5.812

Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.

B R Meyers, E S Srulevitch, J Jacobson, S Z Hirschman
PMCID: PMC185948  PMID: 6318657

Abstract

The pharmacokinetics of ceftriaxone were investigated in six healthy adults. One-gram doses were administered either intramuscularly or intravenously in a crossover design study. Mean peak ceftriaxone concentrations in plasma of 79.2 and 123.2 micrograms/ml were achieved with intramuscular injection and intravenous infusion, respectively, with plasma half-lives of 5.4 and 5.8 h. The urinary recovery of ceftriaxone in the first 24 h was 37% after intravenous infusion and 25% after intramuscular injection.

Full text

PDF
812

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angehrn P., Probst P. J., Reiner R., Then R. L. Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies. Antimicrob Agents Chemother. 1980 Dec;18(6):913–921. doi: 10.1128/aac.18.6.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arvidsson A., Alván G., Angelin B., Borgå O., Nord C. E. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982 Sep;10(3):207–215. doi: 10.1093/jac/10.3.207. [DOI] [PubMed] [Google Scholar]
  3. Bergan T. Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob Agents Chemother. 1978 Dec;14(6):801–806. doi: 10.1128/aac.14.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bolton W. K., Scheld W. M., Spyker D. A., Sande M. A. Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother. 1981 May;19(5):821–825. doi: 10.1128/aac.19.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fiegel P., Becker K. Pharmacokinetics of azlocillin in persons with normal and impaired renal functions. Antimicrob Agents Chemother. 1978 Sep;14(3):288–291. doi: 10.1128/aac.14.3.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Loo J. C., Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970 Jan;59(1):53–55. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
  8. Meyers B. R., Hirschman S. Z., Strougo L., Srulevitch E. Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics. Antimicrob Agents Chemother. 1980 Apr;17(4):608–611. doi: 10.1128/aac.17.4.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Meyers B. R., Hirschman S. Z., Yancovitz S., Ribner B. Pharmacokinetic parameters of sisomicin. Antimicrob Agents Chemother. 1976 Jul;10(1):25–27. doi: 10.1128/aac.10.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Patel I. H., Chen S., Parsonnet M., Hackman M. R., Brooks M. A., Konikoff J., Kaplan S. A. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981 Nov;20(5):634–641. doi: 10.1128/aac.20.5.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Patel I. H., Miller K., Weinfeld R., Spicehandler J. Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy. 1981;27 (Suppl 1):47–56. doi: 10.1159/000238029. [DOI] [PubMed] [Google Scholar]
  12. Patel I. H., Weinfeld R. E., Konikoff J., Parsonnet M. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother. 1982 Jun;21(6):957–962. doi: 10.1128/aac.21.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Seddon M., Wise R., Gillett A. P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980 Aug;18(2):240–242. doi: 10.1128/aac.18.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shannon K., King A., Warren C., Phillips I. In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases. Antimicrob Agents Chemother. 1980 Aug;18(2):292–298. doi: 10.1128/aac.18.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wise R., Gillett A. P., Andrews J. M., Bedford K. A. Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother. 1980 Sep;6(5):595–600. doi: 10.1093/jac/6.5.595. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES